{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:32:36Z","timestamp":1793143956989,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"44","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2023-JC-YB-716"],"award-info":[{"award-number":["2023-JC-YB-716"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundamental Research Funds for the Central Universities"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472665"],"award-info":[{"award-number":["82472665"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundamental Research Funds for the Central Universities"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,11,18]]},"DOI":"10.1038\/s41388-026-03977-5","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:51:43Z","timestamp":1789663903000},"page":"4723-4742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CRISPR\/Cas9 screening revealed BIRC6-AS1\/BIRC6 mediates abiraterone resistance via NHEJ pathway-dependent A20 degradation in prostate cancer"],"prefix":"10.1038","volume":"45","author":[{"given":"Lan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ni","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Tong","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Tong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Yu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Chao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6490-2271","authenticated-orcid":false,"given":"Jing-Lan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1383-3290","authenticated-orcid":false,"given":"Ping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ming","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"3977_CR1","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS De Bono","year":"2011","unstructured":"De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"3977_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42:354\u201373.","journal-title":"Endocr Rev"},{"key":"3977_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01988-y","volume":"23","author":"Y-T Chan","year":"2024","unstructured":"Chan Y-T, Wu J, Lu Y, Li Q, Feng Z, Xu L, et al. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC. Mol Cancer. 2024;23:74.","journal-title":"Mol Cancer"},{"key":"3977_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101275","volume":"82","author":"J Xu","year":"2025","unstructured":"Xu J, Fang S, Dong X, Liang C, Yang R, Zhao Y, et al. Hypoxia-induced upregulation of HIF1A-AS3 promotes MSC transition to cancer-associated fibroblasts and confers drug resistance in gastric cancer. Drug Resistance Updates. 2025;82:101275.","journal-title":"Drug Resistance Updates"},{"key":"3977_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101111","volume":"76","author":"K-L Chen","year":"2024","unstructured":"Chen K-L, Huang S-W, Yao J-J, He S-W, Gong S, Tan X-R, et al. LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein. Drug Resistance Updates. 2024;76:101111.","journal-title":"Drug Resistance Updates"},{"key":"3977_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100975","volume":"69","author":"Q Wen","year":"2023","unstructured":"Wen Q, Huang M, Xie J, Liu R, Miao Q, Huang J, et al. lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2. Drug Resistance Updates. 2023;69:100975.","journal-title":"Drug Resistance Updates"},{"key":"3977_CR7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41580-023-00694-9","volume":"25","author":"J Ferrer","year":"2024","unstructured":"Ferrer J, Dimitrova N. Transcription regulation by long non-coding RNAs: mechanisms and disease relevance. Nat Rev Mol Cell Biol. 2024;25:396\u2013415.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3977_CR8","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.cell.2018.03.052","volume":"173","author":"AC Bester","year":"2018","unstructured":"Bester AC, Lee JD, Chavez A, Lee Y-R, Nachmani D, Vora S, et al. An integrated genome-wide CRISPRa approach to functionalize lncRNAs in drug resistance. Cell. 2018;173:649\u201364.e20.","journal-title":"Cell"},{"key":"3977_CR9","doi-asserted-by":"publisher","unstructured":"Fei T, Chen Y, Xiao T, Li W, Cato L, Zhang P, et al. Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proc Natl Acad Sci USA 2017;114. https:\/\/doi.org\/10.1073\/pnas.1617467114.","DOI":"10.1073\/pnas.1617467114"},{"key":"3977_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35880-y","volume":"14","author":"T Tsujino","year":"2023","unstructured":"Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, et al. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nat Commun. 2023;14:252.","journal-title":"Nat Commun"},{"key":"3977_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan FM, Iorio F, Picco G, Gon\u00e7alves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR\u2013Cas9 screens. Nature. 2019;568:511\u20136.","journal-title":"Nature"},{"key":"3977_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nbt.3235","volume":"33","author":"J Shi","year":"2015","unstructured":"Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol. 2015;33:661\u20137.","journal-title":"Nat Biotechnol"},{"key":"3977_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nbt.3834","volume":"35","author":"K Han","year":"2017","unstructured":"Han K, Jeng EE, Hess GT, Morgens DW, Li A, Bassik MC. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat Biotechnol. 2017;35:463\u201374.","journal-title":"Nat Biotechnol"},{"key":"3977_CR14","doi-asserted-by":"publisher","first-page":"e1000110","DOI":"10.1371\/journal.pgen.1000110","volume":"4","author":"N Bennardo","year":"2008","unstructured":"Bennardo N, Cheng A, Huang N, Stark JM. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet. 2008;4:e1000110.","journal-title":"PLoS Genet"},{"key":"3977_CR15","doi-asserted-by":"crossref","unstructured":"Nakanishi K, Cavallo F, Brunet E, Jasin M. Homologous recombination assay for interstrand cross-link repair. In: Tsubouchi H, edior. DNA Recombination. Totowa, NJ: Humana Press; 2011. p. 283\u201391.","DOI":"10.1007\/978-1-61779-129-1_16"},{"key":"3977_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.113439","volume":"28","author":"L Li","year":"2025","unstructured":"Li L, An X-N, Ruan Y-T, Liang X, Hao J-L, Gao G-X, et al. LncRNA AC021683.2 promotes chemotherapy resistance in acute myeloid leukemia. Iscience. 2025;28:113439.","journal-title":"Iscience"},{"key":"3977_CR17","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/nbt.4283","volume":"36","author":"Y Liu","year":"2018","unstructured":"Liu Y, Cao Z, Wang Y, Guo Y, Xu P, Yuan P, et al. Genome-wide screening for functional long noncoding RNAs in human cells by Cas9 targeting of splice sites. Nat Biotechnol. 2018;36:1203\u201310.","journal-title":"Nat Biotechnol"},{"key":"3977_CR18","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","volume":"17","author":"K Tzelepis","year":"2016","unstructured":"Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Reports. 2016;17:1193\u2013205.","journal-title":"Cell Reports"},{"key":"3977_CR19","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/1078-0432.CCR-16-0718","volume":"23","author":"ISU Luk","year":"2017","unstructured":"Luk ISU, Shrestha R, Xue H, Wang Y, Zhang F, Lin D, et al. BIRC6 targeting as potential therapy for advanced, enzalutamide-resistant prostate cancer. Clin Cancer Res. 2017;23:1542\u201351.","journal-title":"Clin Cancer Res"},{"key":"3977_CR20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13046-022-02541-9","volume":"41","author":"D Li","year":"2022","unstructured":"Li D, Shen L, Zhang X, Chen Z, Huang P, Huang C, et al. LncRNA ELF3-AS1 inhibits gastric cancer by forming a negative feedback loop with SNAI2 and regulates ELF3 mRNA stability via interacting with ILF2\/ILF3 complex. J Exp Clin Cancer Res. 2022;41:332.","journal-title":"J Exp Clin Cancer Res"},{"key":"3977_CR21","doi-asserted-by":"publisher","first-page":"e608","DOI":"10.1002\/ctm2.608","volume":"11","author":"X Zhang","year":"2021","unstructured":"Zhang X, Bustos MA, Gross R, Ramos RI, Takeshima T, Mills GB, et al. Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma. Clin Transl Med. 2021;11:e608.","journal-title":"Clin Transl Med"},{"key":"3977_CR22","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/0008-5472.CAN-17-2143","volume":"78","author":"C Yang","year":"2018","unstructured":"Yang C, Zang W, Tang Z, Ji Y, Xu R, Yang Y, et al. A20\/TNFAIP3 Regulates the DNA damage response and mediates tumor cell resistance to DNA-damaging therapy. Cancer Res. 2018;78:1069\u201382.","journal-title":"Cancer Res"},{"key":"3977_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jsbmb.2010.11.005","volume":"125","author":"TS Vasaitis","year":"2011","unstructured":"Vasaitis TS, Bruno RD, Njar VCO. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol. 2011;125:23\u201331.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3977_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11912-013-0300-1","volume":"15","author":"H Zhu","year":"2013","unstructured":"Zhu H, Garcia JA. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor. Curr Oncol Rep. 2013;15:105\u201312.","journal-title":"Curr Oncol Rep"},{"key":"3977_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.eururo.2018.01.035","volume":"74","author":"ES Antonarakis","year":"2018","unstructured":"Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, et al. Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. Eur Urol. 2018;74:218\u201325.","journal-title":"Eur Urol"},{"key":"3977_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.eururo.2024.09.008","volume":"87","author":"E Francini","year":"2025","unstructured":"Francini E, Agarwal N, Castro E, Cheng HH, Chi KN, Clarke N, et al. Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review. Eur Urol. 2025;87:29\u201346.","journal-title":"Eur Urol"},{"key":"3977_CR27","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","volume":"30","author":"M Hussain","year":"2024","unstructured":"Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, et al. Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin Cancer Res. 2024;30:4318\u201328.","journal-title":"Clin Cancer Res"},{"key":"3977_CR28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.euo.2024.02.005","volume":"7","author":"J Xie","year":"2024","unstructured":"Xie J, Guo H, Dong B, Chen W, Jin C, Xu Q, et al. Olaparib combined with abiraterone versus olaparib monotherapy for patients with metastatic castration-resistant prostate cancer progressing after abiraterone and harboring DNA damage repair deficiency: a multicenter real-world study. Eur Urol Oncol. 2024;7:1088\u201396.","journal-title":"Eur Urol Oncol"},{"key":"3977_CR29","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jamaoncol.2016.0494","volume":"2","author":"AW Wyatt","year":"2016","unstructured":"Wyatt AW, Azad AA, Volik SV, Annala M, Beja K, McConeghy B, et al. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol. 2016;2:1598.","journal-title":"JAMA Oncol"},{"key":"3977_CR30","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1038\/s41388-024-03148-4","volume":"43","author":"S Sardar","year":"2024","unstructured":"Sardar S, McNair CM, Ravindranath L, Chand SN, Yuan W, Bogdan D, et al. AR coactivators, CBP\/p300, are critical mediators of DNA repair in prostate cancer. Oncogene. 2024;43:3197\u2013213.","journal-title":"Oncogene"},{"key":"3977_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-1146-4","volume":"19","author":"X Yang","year":"2020","unstructured":"Yang X, Zhang S, He C, Xue P, Zhang L, He Z, et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol Cancer. 2020;19:46.","journal-title":"Mol Cancer"},{"key":"3977_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-019-0773-y","volume":"12","author":"Q Hua","year":"2019","unstructured":"Hua Q, Jin M, Mi B, Xu F, Li T, Zhao L, et al. LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p\/c-Myc axis. J Hematol Oncol. 2019;12:91.","journal-title":"J Hematol Oncol"},{"key":"3977_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103362","volume":"77","author":"Z Xin","year":"2024","unstructured":"Xin Z, Hu C, Zhang C, Liu M, Li J, Sun X, et al. LncRNA-HMG incites colorectal cancer cells to chemoresistance via repressing p53-mediated ferroptosis. Redox Biol. 2024;77:103362.","journal-title":"Redox Biol"},{"key":"3977_CR34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41698-024-00675-x","volume":"8","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Li B, Zhang X, Zhao H, Xue W, Yuan Z, et al. M2 macrophage-derived lncRNA NORAD in EVs promotes NSCLC progression via miR-520g-3p\/SMIM22\/GALE axis. npj Precis Onc. 2024;8:185.","journal-title":"npj Precis Onc"},{"key":"3977_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02826-6","volume":"21","author":"Z Zheng","year":"2023","unstructured":"Zheng Z, Wu M, Li H, Xu W, Yang M, Pan K, et al. Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3\/AR\/RASGRP3 axis. BMC Med. 2023;21:132.","journal-title":"BMC Med"},{"key":"3977_CR36","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1093\/nar\/gkad143","volume":"51","author":"T-W Chuang","year":"2023","unstructured":"Chuang T-W, Su C-H, Wu P-Y, Chang Y-M, Tarn W-Y. LncRNA HOTAIRM1 functions in DNA double-strand break repair via its association with DNA repair and mRNA surveillance factors. Nucleic Acids Res. 2023;51:3166\u201384.","journal-title":"Nucleic Acids Res"},{"key":"3977_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100866","volume":"65","author":"GC Eptaminitaki","year":"2022","unstructured":"Eptaminitaki GC, Stellas D, Bonavida B, Baritaki S. Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability. Drug Resistance Updates. 2022;65:100866.","journal-title":"Drug Resistance Updates"},{"key":"3977_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09784-9","volume":"10","author":"J Luo","year":"2019","unstructured":"Luo J, Wang K, Yeh S, Sun Y, Liang L, Xiao Y, et al. LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2\/STAT3 signaling. Nat Commun. 2019;10:2571.","journal-title":"Nat Commun"},{"key":"3977_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59886-w","volume":"16","author":"A Tamura","year":"2025","unstructured":"Tamura A, Yamagata K, Kono T, Fujimoto M, Fuchigami T, Nishimura M, et al. p53-inducible lncRNA LOC644656 causes genotoxic stress-induced stem cell maldifferentiation and cancer chemoresistance. Nat Commun. 2025;16:4818.","journal-title":"Nat Commun"},{"key":"3977_CR40","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/ncb3643","volume":"19","author":"F Michelini","year":"2017","unstructured":"Michelini F, Pitchiaya S, Vitelli V, Sharma S, Gioia U, Pessina F, et al. Damage-induced lncRNAs control the DNA damage response through interaction with DDRNAs at individual double-strand breaks. Nat Cell Biol. 2017;19:1400\u201311.","journal-title":"Nat Cell Biol"},{"key":"3977_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401939","volume":"11","author":"S Kaimala","year":"2024","unstructured":"Kaimala S, Lootah SS, Mehra N, Kumar CA, Marzooqi SA, Sampath P, et al. The long non-coding RNA obesity-related (Obr) contributes to lipid metabolism through epigenetic regulation. Adv Sci. 2024;11:2401939.","journal-title":"Adv Sci"},{"key":"3977_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55539-6","volume":"16","author":"JA Oo","year":"2025","unstructured":"Oo JA, Warwick T, P\u00e1lfi K, Lam F, McNicoll F, Prieto-Garcia C, et al. Long non-coding RNAs direct the SWI\/SNF complex to cell type-specific enhancers. Nat Commun. 2025;16:131.","journal-title":"Nat Commun"},{"key":"3977_CR43","doi-asserted-by":"publisher","first-page":"12375","DOI":"10.1074\/jbc.R116.760884","volume":"292","author":"NW Mathy","year":"2017","unstructured":"Mathy NW, Chen X-M. Long non-coding RNAs (lncRNAs) and their transcriptional control of inflammatory responses. J Biol Chem. 2017;292:12375\u201382.","journal-title":"J Biol Chem"},{"key":"3977_CR44","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1158\/0008-5472.CAN-18-3418","volume":"79","author":"H Zhang","year":"2019","unstructured":"Zhang H, Zhang N, Liu Y, Su P, Liang Y, Li Y, et al. Epigenetic regulation of NAMPT by NAMPT-AS drives metastatic progression in triple-negative breast cancer. Cancer Res. 2019;79:3347\u201359.","journal-title":"Cancer Res"},{"key":"3977_CR45","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.celrep.2015.08.069","volume":"13","author":"A Zhang","year":"2015","unstructured":"Zhang A, Zhao JC, Kim J, Fong K, Yang YA, Chakravarti D, et al. LncRNA HOTAIR enhances the androgen-receptor-mediated transcriptional program and drives castration-resistant prostate cancer. Cell Rep. 2015;13:209\u201321.","journal-title":"Cell Rep"},{"key":"3977_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04144-2","volume":"12","author":"B Zhang","year":"2021","unstructured":"Zhang B, Zhang M, Shen C, Liu G, Zhang F, Hou J, et al. LncRNA PCBP1-AS1-mediated AR\/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance. Cell Death Dis. 2021;12:856.","journal-title":"Cell Death Dis"},{"key":"3977_CR47","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1158\/0008-5472.CAN-18-0688","volume":"78","author":"X Li","year":"2018","unstructured":"Li X, Wang X, Song W, Xu H, Huang R, Wang Y, et al. Oncogenic Properties of NEAT1 in prostate cancer cells depend on the CDC5L\u2013AGRN transcriptional regulation circuit. Cancer Res. 2018;78:4138\u201349.","journal-title":"Cancer Res"},{"key":"3977_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45222-1","volume":"15","author":"S-S Liu","year":"2024","unstructured":"Liu S-S, Jiang T-X, Bu F, Zhao J-L, Wang G-F, Yang G-H, et al. Molecular mechanisms underlying the BIRC6-mediated regulation of apoptosis and autophagy. Nat Commun. 2024;15:891.","journal-title":"Nat Commun"},{"key":"3977_CR49","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1126\/science.ade8840","volume":"379","author":"L Dietz","year":"2023","unstructured":"Dietz L, Ellison CJ, Riechmann C, Cassidy CK, Felfoldi FD, Pinto-Fern\u00e1ndez A, et al. Structural basis for SMAC-mediated antagonism of caspase inhibition by the giant ubiquitin ligase BIRC6. Science. 2023;379:1112\u20137.","journal-title":"Science"},{"key":"3977_CR50","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1126\/science.ade5750","volume":"379","author":"M Hunkeler","year":"2023","unstructured":"Hunkeler M, Jin CY, Fischer ES. Structures of BIRC6-client complexes provide a mechanism of SMAC-mediated release of caspases. Science. 2023;379:1105\u201311.","journal-title":"Science"},{"key":"3977_CR51","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1126\/science.ade8873","volume":"379","author":"JF Ehrmann","year":"2023","unstructured":"Ehrmann JF, Grabarczyk DB, Heinke M, Deszcz L, Kurzbauer R, Hudecz O, et al. Structural basis for regulation of apoptosis and autophagy by the BIRC6\/SMAC complex. Science. 2023;379:1117\u201323.","journal-title":"Science"},{"key":"3977_CR52","doi-asserted-by":"crossref","unstructured":"G\u00f3mez Bergna SM, Marchesini A, Amor\u00f3s Morales LC, Arr\u00edas PN, Farina HG, Romanowski V, et al. Exploring the role of the inhibitor of apoptosis BIRC6 in breast cancer: a database analysis. JCO Clinical Cancer Informatics. 2022;e2200093.","DOI":"10.1200\/CCI.22.00093"},{"key":"3977_CR53","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.omtn.2021.09.011","volume":"26","author":"Y Li","year":"2021","unstructured":"Li Y, Tan Y, Wen L, Xing Z, Wang C, Zhang L, et al. Overexpression of BIRC6 driven by EGF-JNK-HECTD1 signaling is a potential therapeutic target for triple-negative breast cancer. Mol Therapy Nucleic Acids. 2021;26:798\u2013812.","journal-title":"Mol Therapy Nucleic Acids"},{"key":"3977_CR54","doi-asserted-by":"publisher","first-page":"e0125281","DOI":"10.1371\/journal.pone.0125281","volume":"10","author":"T Hu","year":"2015","unstructured":"Hu T, Weng S, Tang W, Xue R, Chen S, Cai G, et al. Overexpression of BIRC6 Is a predictor of prognosis for colorectal cancer. PLoS ONE. 2015;10:e0125281.","journal-title":"PLoS ONE"},{"key":"3977_CR55","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298\u2013305.","journal-title":"Nat Med"},{"key":"3977_CR56","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.molcel.2019.01.018","volume":"73","author":"Z Ding","year":"2019","unstructured":"Ding Z, Xu C, Sahu I, Wang Y, Fu Z, Huang M, et al. Structural snapshots of 26S proteasome reveal tetraubiquitin-induced conformations. Mol Cell. 2019;73:1150\u201361.e6.","journal-title":"Mol Cell"},{"key":"3977_CR57","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.molcel.2025.02.021","volume":"85","author":"L Kiss","year":"2025","unstructured":"Kiss L, James LC, Schulman BA. UbiREAD deciphers proteasomal degradation code of homotypic and branched K48 and K63 ubiquitin chains. Mol Cell. 2025;85:1467\u201376.e6.","journal-title":"Mol Cell"},{"key":"3977_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aar8133","volume":"11","author":"P Liu","year":"2018","unstructured":"Liu P, Gan W, Su S, Hauenstein AV, Fu T, Brasher B, et al. K63-linked polyubiquitin chains bind to DNA to facilitate DNA damage repair. Sci Signal. 2018;11:eaar8133.","journal-title":"Sci Signal"},{"key":"3977_CR59","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41418-025-01480-0","volume":"32","author":"L Xia","year":"2025","unstructured":"Xia L, Xing Y, Ye X, Wu Y, Yang Y, Yin Z, et al. TRIM21-driven K63-linked ubiquitination of RBM38c, as a novel interactor of BECN1, contributes to DNA damage-induced autophagy. Cell Death Differ. 2025;32:1317\u201335.","journal-title":"Cell Death Differ"},{"key":"3977_CR60","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1038\/onc.2014.229","volume":"34","author":"B Zhu","year":"2015","unstructured":"Zhu B, Yan K, Li L, Lin M, Zhang S, He Q, et al. K63-linked ubiquitination of FANCG is required for its association with the Rap80-BRCA1 complex to modulate homologous recombination repair of DNA interstand crosslinks. Oncogene. 2015;34:2867\u201378.","journal-title":"Oncogene"},{"key":"3977_CR61","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.it.2009.05.007","volume":"30","author":"L Vereecke","year":"2009","unstructured":"Vereecke L, Beyaert R, Van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009;30:383\u201391.","journal-title":"Trends Immunol"},{"key":"3977_CR62","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.immuni.2025.02.007","volume":"58","author":"C Luo","year":"2025","unstructured":"Luo C, Zhang R, Guo R, Wu L, Xue T, He Y, et al. Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells. Immunity. 2025;58:745\u201365.e9.","journal-title":"Immunity"},{"key":"3977_CR63","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41392-023-01545-x","volume":"8","author":"M Luo","year":"2023","unstructured":"Luo M, Wang X, Wu S, Yang C, Su Q, Huang L, et al. A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block \u201ceat-me\u201d signal. Sig Transduct Target Ther. 2023;8:312.","journal-title":"Sig Transduct Target Ther"},{"key":"3977_CR64","first-page":"1533","volume":"13","author":"M-T Han","year":"2023","unstructured":"Han M-T, Pei H, Sun Q-Q, Wang C-L, Li P, Xie Y-Y, et al. ZY-444 inhibits the growth and metastasis of prostate cancer by targeting TNFAIP3 through TNF signaling pathway. Am J Cancer Res. 2023;13:1533\u201346.","journal-title":"Am J Cancer Res"},{"key":"3977_CR65","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","volume":"53","author":"Y Perez-Riverol","year":"2025","unstructured":"Perez-Riverol Y, Bandla C, Kundu DJ, Kamatchinathan S, Bai J, Hewapathirana S, et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 2025;53:D543\u201353.","journal-title":"Nucleic Acids Res"},{"key":"3977_CR66","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, et al. iProX: an integrated proteome resource. Nucleic Acids Res. 2019;47:D1211\u20137.","journal-title":"Nucleic Acids Res"},{"key":"3977_CR67","first-page":"D1145","volume":"48","author":"EW Deutsch","year":"2020","unstructured":"Deutsch EW, Bandeira N, Sharma V, Perez-Riverol Y, Carver JJ, Kundu DJ, et al. The ProteomeXchange consortium in 2020: Enabling \u2018big data\u2019 approaches in proteomics. Nucleic Acids Res. 2020;48:D1145\u201352.","journal-title":"Nucleic Acids Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03977-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03977-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03977-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:02:05Z","timestamp":1793142125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03977-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":67,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2026,11,18]]}},"alternative-id":["3977"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03977-5","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors approved for the publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors confirm that all methods were performed in accordance with the relevant guidelines and regulations. Animal experiments were performed according with the approved protocols by the ethical committee of Shaanxi Normal University (Approval No. 2024-076). This study did not involve the recruitment of human participants or the collection of human tissue samples. All human-derived data were obtained from publicly available datasets.","order":3,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}